Shares of Precipio (NASDAQ:PRPO) saw unusually-strong trading volume on Tuesday . Approximately 1,345,547 shares changed hands during trading, an increase of 381% from the previous session’s volume of 279,829 shares.The stock last traded at $2.15 and had previously closed at $1.91.
Separately, Maxim Group started coverage on shares of Precipio in a report on Friday, November 22nd. They issued a “buy” rating and a $4.00 price objective for the company.
The business’s 50-day simple moving average is $2.01 and its 200 day simple moving average is $2.49. The company has a debt-to-equity ratio of 0.05, a quick ratio of 0.60 and a current ratio of 0.64.
Precipio (NASDAQ:PRPO) last posted its quarterly earnings data on Wednesday, November 13th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter. The company had revenue of $0.78 million during the quarter. Precipio had a negative net margin of 525.32% and a negative return on equity of 94.75%.
A number of large investors have recently made changes to their positions in PRPO. BlackRock Inc. acquired a new stake in Precipio in the second quarter worth approximately $47,000. Morgan Stanley bought a new position in Precipio during the 2nd quarter valued at $86,000. SeaCrest Wealth Management LLC boosted its stake in Precipio by 8.7% during the 3rd quarter. SeaCrest Wealth Management LLC now owns 59,050 shares of the biotechnology company’s stock valued at $154,000 after purchasing an additional 4,750 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of Precipio during the 3rd quarter valued at $55,000. 4.23% of the stock is currently owned by hedge funds and other institutional investors.
Precipio Company Profile (NASDAQ:PRPO)
Precipio, Inc, a cancer diagnostics company, provides diagnostic products and services to the oncology market. It also develops a platform to eradicate the problem of misdiagnosis within academic institutions. In addition, the company delivers diagnostic information to physicians and their patients. It has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment, as well as PerkinElmer.
Further Reading: Do You Need a Fiduciary?
Receive News & Ratings for Precipio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precipio and related companies with MarketBeat.com's FREE daily email newsletter.